Advancements in cancer diagnosis and treatment

Medical technology continues to advance in the diagnosis and treatment of various cancers. Developments include Contrast Enhanced Mammography, which uses iodine-based dye to identify cancers in dense breast tissue more effectively than standard mammograms, and robotic surgery for treating lymphedema by reattaching lymphatic vessels.

Further technological progress includes the use of robotic surgery in urology for prostate, kidney, and bladder cancers to improve precision and preserve vital functions such as urinary control and renal tissue. Diagnostic innovations like liquid biopsies, which detect circulating tumor DNA (ctDNA) in the blood, are being utilized to monitor treatment resistance and predict metastasis risks.

In the field of liver cancer, specifically advanced hepatocellular carcinoma (HCC), the ‘Stride’ immunotherapy regimen—comprising tremelimumab and durvalumab—has shown long-term efficacy. Data from the Himalaya study involving nearly 1,200 patients reported a 6-year survival rate of 17.1%, a result described by experts as a “potential paradigm shift” for patients in intermediate stages. Treating HCC remains uniquely challenging as it often develops in cirrhotic livers, necessitating therapies that target tumors without compromising liver function. The Emerald-3 study is also noted for combining immunotherapy with anti-angiogenic drugs to provide systemic control alongside standard local treatments.

Additionally, the Edison Histotripsy System, a non-invasive ultrasound technology, has received FDA De Novo authorization for treating liver tumors, with clinical studies reporting a 95.7% technical success rate for both primary and metastatic tumors. Other interventional radiology methods, such as ablation and transarterial chemoembolization, also remain part of the treatment landscape.